LATISSE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Latisse, and when can generic versions of Latisse launch?
Latisse is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has seventeen patent family members in eight countries.
The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Latisse
A generic version of LATISSE was approved as bimatoprost by APOTEX on December 1st, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LATISSE?
- What are the global sales for LATISSE?
- What is Average Wholesale Price for LATISSE?
Summary for LATISSE
| International Patents: | 17 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,457 |
| Drug Prices: | Drug price information for LATISSE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LATISSE |
| What excipients (inactive ingredients) are in LATISSE? | LATISSE excipients list |
| DailyMed Link: | LATISSE at DailyMed |
Recent Clinical Trials for LATISSE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tulane University | Early Phase 1 |
| Allergan | Early Phase 1 |
| Allergan | Phase 3 |
Pharmacology for LATISSE
| Drug Class | Prostaglandin Analog |
Paragraph IV (Patent) Challenges for LATISSE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LATISSE | Topical Solution | bimatoprost | 0.03% | 022369 | 1 | 2010-05-03 |
US Patents and Regulatory Information for LATISSE
LATISSE is protected by two US patents.
Patents protecting LATISSE
Method of enhancing hair growth
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF STIMULATING HAIR GROWTH
Method of enhancing hair growth
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF INCREASING HAIR GROWTH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | LATISSE | bimatoprost | SOLUTION/DROPS;TOPICAL | 022369-001 | Dec 24, 2008 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LATISSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | LATISSE | bimatoprost | SOLUTION/DROPS;TOPICAL | 022369-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LATISSE | bimatoprost | SOLUTION/DROPS;TOPICAL | 022369-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LATISSE | bimatoprost | SOLUTION/DROPS;TOPICAL | 022369-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LATISSE | bimatoprost | SOLUTION/DROPS;TOPICAL | 022369-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for LATISSE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH & Co. KG | Lumigan | bimatoprost | EMEA/H/C/000391 Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., |
Authorised | no | no | no | 2002-03-08 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for LATISSE
See the table below for patents covering LATISSE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2014043451 | COMPOSITIONS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS, AND TREATMENT METHODS THEREFOR | ⤷ Sign Up |
| Germany | 10299037 | ⤷ Sign Up | |
| Canada | 2475106 | PROCEDE POUR AMELIORER LA CROISSANCE CAPILLAIRE (METHOD OF ENHANCING HAIR GROWTH) | ⤷ Sign Up |
| China | 101897700 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LATISSE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | SPC023/2002 | Ireland | ⤷ Sign Up | SPC023/2002: 20040929, EXPIRES: 20170307 |
| 0660716 | 02C0033 | France | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| 0660716 | SPC/GB02/035 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| 0660716 | 90957 | Luxembourg | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
